Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05111223

Testing the Contribution of Orbitofrontal Cortex Networks to Decision-making

This research study examines the contribution of orbitofrontal cortex (OFC) networks to decision-making.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northwestern University

Chicago, Illinois, 60657, United States

Location status: Recruiting

Location contact

Christina Zelano, PhD

PRINCIPAL_INVESTIGATOR

Daria Porter, PhD

CONTACT

[email protected]

312-503-4223

About this study

This study will combine functional magnetic resonance imaging (fMRI), non-invasive transcranial magnetic stimulation (TMS), olfactory stimuli, and a devaluation task to define the specific contributions of orbitofrontal cortex (OFC) networks in outcome-guided behavior. We will use network-targeted TMS to modulate activity within anterior OFC and posterior OFC networks, examining if they have different contributions to decision-making. This is a randomized, between-subjects design.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 40 years old
  • Right-handed
  • Fluent English speakers

Exclusion criteria

  • History of significant neurological conditions (e.g., epilepsy, dementia, multiple sclerosis, brain tumors, etc.)
  • History of major psychiatric conditions (e.g., general anxiety disorder, depression, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, substance use disorder, etc.)
  • Significant medical illnesses (e.g., cancer, meningitis, chronic obstructive pulmonary disease, cardiovascular disease, etc.)
  • Significant cerebrovascular risk factors (e.g., hypertension, diabetes, elevated cholesterol, etc.)
  • Current use of psychoactive medications (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, citalopram, escitalopram, fluoxetine, diazepam, etc.)
  • Smell or taste dysfunction
  • History of significant allergies requiring hospitalization for treatment
  • History of severe asthma requiring hospitalization for treatment
  • Habitual smoking
  • History of eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge-eating disorder, etc.)
  • Dieting or fasting
  • Magnetic implants (e.g., shunts or stents, aneurysm clips, surgical clips, cochlear implants, metal bone/joint pins, plates and screws, eyelid spring or wires, etc.)
  • Electronic devices (e.g., implanted cardiac defibrillator, cardiac pacemaker, deep brain/spinal cord or nerve stimulator, internal electrodes/wires, medication infusion devices, etc.)
  • History of metal working without proper eye protection, or injury with metal shrapnel or metal slivers
  • Claustrophobia
  • Pregnancy
  • Predisposition to seizures (e.g., personal history of seizures, family history of seizures epilepsy, pregnancy, alcoholism, etc.)
  • Use of medications that increase the likelihood of seizures (e.g., bupropion SR, citalopram, duloxetine, ketamine, gamma-hydroxybutyrate, etc.)
  • History of surgical procedures performed on the brain or spinal cord
  • History of severe head trauma followed by loss of consciousness
  • History of fainting spells or syncope
  • Hearing problems or tinnitus

Treatment and study plan

Real transcranial magnetic stimulation (TMS) before conditioning

Device

Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.

Real transcranial magnetic stimulation (TMS) before devaluation test

Device

Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.

Sham Transcranial Magnetic Stimulation (TMS)

Device

Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.

Primary outcomes

  1. Behavior on devaluation task

    Time frame: 1 hour after intervention

    Percentage of cues predicting non-devalued vs devalued odors chosen during the devaluation task.

  2. Resting-state functional magnetic resonance imaging

    Time frame: 1 hour after intervention

    Resting-state activity determined by functional magnetic resonance imaging.

Study contacts

Contact information is provided by the study sponsor or research team.

Christina Zelano, PhD

CONTACT

[email protected]

312-503-4437

Greg Lane, PhD

CONTACT

312-503-7244

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Nov 8, 2021
Registry last updated
Aug 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.